Skip to main content
SpringerLink
Log in

Histological Response and Biological Markers

  • Chapter
Malignant Pediatric Bone Tumors - Treatment & Management

Part of the book series: Pediatric Oncology ((PEDIATRICO))

  • 1064 Accesses

Abstract

The optimization of treatment strategies for patients with bony tumors has proven to be elusive. Though patients with localized disease have achieved increased survival rates with the most recent therapeutic revolutions of dose escalation and interval compression, prognosis continues to remain significantly poor for those patients with metastatic disease. Stratification of bone tumor patients into risk categories is one method to target more intensified treatment regimens for patients with historically worse outcomes, while sparing patients with lower-risk disease from toxicities associated with highly aggressive therapies. Strategies to risk stratify these patients must involve incorporation of their tumor biology, including the presence or absence of significant biological markers, and their interval responses to treatment. The prognostic implications of biological markers and the histological response to neoadjuvant chemotherapy for bone tumors have been extensively studied. As further designations of risk groups for patients evolve, it has become apparent that these are crucial factors to consider.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Abudu A, Mangham DC, Reynolds GM, Pynsent PB, Tillman RM, Carter SR, Grimer RJ (1999) Overexpression of p53 protein in primary Ewing’s sarcoma of bone: relationship to tumour stage, response and prognosis. Br J Cancer 79(7-8):1185–1189. doi:10.1038/sj.bjc.6690190

    CAS  PubMed Central  PubMed  Google Scholar 

  • Altman DG, McShane LM, Sauerbrei W, Taube SE (2012) Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration. PLoS Med 9(5), e1001216. doi:10.1371/journal.pmed.1001216

    PubMed Central  PubMed  Google Scholar 

  • Ambroszkiewicz J, Gajewska J, Klepacka T, Bilska K, Wozniak W, Laskowska-Klita T (2006) Biochemical bone turnover markers in patients with conventional and nonconventional osteosarcoma. Pol Merkur Lekarski 21(124):330–334

    CAS  PubMed  Google Scholar 

  • Ambroszkiewicz J, Gajewska J, Klepacka T, Chelchowska M, Laskowska-Klita T, Wozniak W (2010a) Clinical utility of biochemical bone turnover markers in children and adolescents with osteosarcoma. Adv Med Sci 55(2):266–272. doi:10.2478/v10039-010-0043-2

    CAS  PubMed  Google Scholar 

  • Ambroszkiewicz J, Gajewska J, Klepacka T, Chelchowska M, Laskowska-Klita T, Wozniak W (2010b) A comparison of serum concentrations of biochemical bone turnover markers in patients with osteosarcoma with good and poor prognosis. Pol Merkur Lekarski 29(169):19–26

    CAS  PubMed  Google Scholar 

  • Anninga JK, Gelderblom H, Fiocco M, Kroep JR, Taminiau AHM, Hogendoorn PCW, Egeler RM (2011) Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand? Eur J Cancer 47(16):2431–2445, doi: http://dx.doi.org/10.1016/j.ejca.2011.05.030

    CAS  PubMed  Google Scholar 

  • Antillon-Klussmann F, Garcia-Delgado M, Villa-Elizaga I, Sierrasesumaga L (1995) Mutational activation of ras genes is absent in pediatric osteosarcoma. Cancer Genet Cytogenet 79(1):49–53, doi: 016546089400115R [pii]

    CAS  PubMed  Google Scholar 

  • Armengol G, Tarkkanen M, Virolainen M, Forus A, Valle J, Bohling T, Asko-Seljavaara S, Blomqvist C, Elomaa I, Karaharju E, Kivioja AH, Siimes MA, Tukiainen E, Caballín MR, Myklebost O, Knuutila S (1997) Recurrent gains of 1q, 8 and 12 in the Ewing family of tumours by comparative genomic hybridization. Br J Cancer 75(10):1403–1409

    CAS  PubMed Central  PubMed  Google Scholar 

  • Ash S, Luria D, Cohen IJ, Goshen Y, Toledano H, Issakov J, Yaniv I, Avigad S (2011) Excellent prognosis in a subset of patients with Ewing sarcoma identified at diagnosis by CD56 using flow cytometry. Clin Cancer Res 17(9):2900–2907. doi:10.1158/1078-0432.CCR-10-3069

    CAS  PubMed  Google Scholar 

  • Bacci G, Ferrari S, Bertoni F, Picci P, Bacchini P, Longhi A, Donati D, Forni C, Campanacci L, Campanacci M (2001) Histologic response of high-grade nonmetastatic osteosarcoma of the extremity to chemotherapy. Clin Orthop Relat Res (386):186–196

    Google Scholar 

  • Bacci G, Ferrari S, Longhi A, Picci P, Mercuri M, Alvegard TA, Saeter G, Donati D, Manfrini M, Lari S, Briccoli A, Forni C (2002a) High dose ifosfamide in combination with high dose methotrexate, adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group pilot study. J Chemother 14(2):198–206. doi:10.1179/joc.2002.14.2.198

    CAS  PubMed  Google Scholar 

  • Bacci G, Longhi A, Ferrari S, Lari S, Manfrini M, Donati D, Forni C, Versari M (2002b) Prognostic significance of serum alkaline phosphatase in osteosarcoma of the extremity treated with neoadjuvant chemotherapy: recent experience at Rizzoli Institute. Oncol Rep 9(1):171–175

    PubMed  Google Scholar 

  • Bacci G, Ferrari S, Longhi A, Donati D, Barbieri E, Forni C, Bertoni F, Manfrini M, Giacomini S, Bacchini P (2004a) Role of surgery in local treatment of Ewing’s sarcoma of the extremities in patients undergoing adjuvant and neoadjuvant chemotherapy. Oncol Rep 11(1):111–120

    PubMed  Google Scholar 

  • Bacci G, Forni C, Longhi A, Ferrari S, Donati D, De Paolis M, Barbieri E, Pignotti E, Rosito P, Versari M (2004b) Long-term outcome for patients with non-metastatic Ewing’s sarcoma treated with adjuvant and neoadjuvant chemotherapies. 402 patients treated at Rizzoli between 1972 and 1992. Eur J Cancer 40(1):73–83

    CAS  PubMed  Google Scholar 

  • Bacci G, Longhi A, Ferrari S, Mercuri M, Versari M, Bertoni F (2006a) Prognostic factors in non-metastatic Ewing’s sarcoma tumor of bone: an analysis of 579 patients treated at a single institution with adjuvant or neoadjuvant chemotherapy between 1972 and 1998. Acta Oncol 45(4):469–475. doi:10.1080/02841860500519760

    PubMed  Google Scholar 

  • Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P (2006b) Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer 106(5):1154–1161. doi:10.1002/cncr.21724

    PubMed  Google Scholar 

  • Barrios C, Castresana JS, Ruiz J, Kreicbergs A (1993) Amplification of c-myc oncogene and absence of c-Ha-ras point mutation in human bone sarcoma. J Orthop Res 11(4):556–563. doi:10.1002/jor.1100110410

    CAS  PubMed  Google Scholar 

  • Bauer HC, Kreicbergs A, Silfversward C, Tribukait B (1989) Ploidy and morphology in osteosarcoma. Anal Quant Cytol Histol 11(2):96–103

    CAS  PubMed  Google Scholar 

  • Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M, Winkelmann W, Zoubek A, Jürgens H, Winkler K (2002) Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 20(3):776–790

    PubMed  Google Scholar 

  • Biondi A, Valsecchi MG, Seriu T, D’Aniello E, Willemse MJ, Fasching K, Pannunzio A, Gadner H, Schrappe M, Kamps WA, Bartram CR, van Dongen JJ, Panzer-Grumayer ER (2000) Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM study group. Leukemia 14(11):1939–1943

    CAS  PubMed  Google Scholar 

  • Biswas B, Rastogi S, Khan SA, Mohanti BK, Sharma DN, Sharma MC, Mridha AR, Bakhshi S (2014) Outcomes and prognostic factors for Ewing-family tumors of the extremities. J Bone Joint Surg Am 96(10):841–849. doi:10.2106/JBJS.M.00411

    PubMed  Google Scholar 

  • Borowitz MJ, Devidas M, Hunger SP, Bowman WP, Carroll AJ, Carroll WL, Linda S, Martin PL, Pullen DJ, Viswanatha D, Willman CL, Winick N, Camitta BM (2008) Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children’s Oncology Group study. Blood 111(12):5477–5485. doi:10.1182/blood-2008-01-132837

    CAS  PubMed Central  PubMed  Google Scholar 

  • Burrow S, Andrulis IL, Pollak M, Bell RS (1998) Expression of insulin-like growth factor receptor, IGF-1, and IGF-2 in primary and metastatic osteosarcoma. J Surg Oncol 69(1):21–27. doi:10.1002/(SICI)1096-9098(199809)69:1<21::AID-JSO5>3.0.CO;2-M [pii]

  • Byun BH, Kong CB, Park J, Seo Y, Lim I, Choi CW, Cho WH, Jeon DG, Koh JS, Lee SY, Lim SM (2013) Initial metabolic tumor volume measured by 18F-FDG PET/CT can predict the outcome of osteosarcoma of the extremities. J Nucl Med 54(10):1725–1732. doi:10.2967/jnumed.112.117697

    CAS  PubMed  Google Scholar 

  • Chandrasekar CR, Grimer RJ, Carter SR, Tillman RM, Abudu AT, Jeys LM (2011) Outcome of pathologic fractures of the proximal femur in nonosteogenic primary bone sarcoma. Eur J Surg Oncol 37(6):532–536. doi:10.1016/j.ejso.2011.02.007

    CAS  PubMed  Google Scholar 

  • Coffin CM, Lowichik A, Zhou H (2005) Treatment effects in pediatric soft tissue and bone tumors: practical considerations for the pathologist. Am J Clin Pathol 123(1):75–90

    PubMed  Google Scholar 

  • Cotterill SJ, Ahrens S, Paulussen M, Jurgens HF, Voute PA, Gadner H, Craft AW (2000) Prognostic factors in Ewing’s tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing’s Sarcoma Study Group. J Clin Oncol 18(17):3108–3114

    CAS  PubMed  Google Scholar 

  • de Alava E, Antonescu CR, Panizo A, Leung D, Meyers PA, Huvos AG, Pardo-Mindán FJ, Healey JH, Ladanyi M (2000) Prognostic impact of P53 status in Ewing sarcoma. Cancer 89(4):783–792

    PubMed  Google Scholar 

  • Diller L, Kassel J, Nelson CE, Gryka MA, Litwak G, Gebhardt M, Bressac B, Ozturk M, Baker SJ, Vogelstein B et al (1990) p53 functions as a cell cycle control protein in osteosarcomas. Mol Cell Biol 10(11):5772–5781

    CAS  PubMed Central  PubMed  Google Scholar 

  • Dubois SG, Epling CL, Teague J, Matthay KK, Sinclair E (2010) Flow cytometric detection of Ewing sarcoma cells in peripheral blood and bone marrow. Pediatr Blood Cancer 54(1):13–18. doi:10.1002/pbc.22245

    PubMed Central  PubMed  Google Scholar 

  • Dutour A, Decouvelaere AV, Monteil J, Duclos ME, Roualdes O, Rousseau R, Marec-Berard P (2009) 18F-FDG PET SUVmax correlates with osteosarcoma histologic response to neoadjuvant chemotherapy: preclinical evaluation in an orthotopic rat model. J Nucl Med 50(9):1533–1540. doi:10.2967/jnumed.109.062356

    CAS  PubMed  Google Scholar 

  • Ferracini R, Di Renzo MF, Scotlandi K, Baldini N, Olivero M, Lollini P, Cremona O, Campanacci M, Comoglio PM (1995) The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit. Oncogene 10(4):739–749

    CAS  PubMed  Google Scholar 

  • Ferrari S, Bertoni F, Mercuri M, Picci P, Giacomini S, Longhi A, Bacci G (2001) Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity: an analysis of 300 patients treated at the Rizzoli Institute. Ann Oncol 12(8):1145–1150

    CAS  PubMed  Google Scholar 

  • Ferreira BI, Alonso J, Carrillo J, Acquadro F, Largo C, Suela J, Teixeira MR, Cerveira N, Molares A, Goméz-López G, Pestaña A, Sastre A, Garcia-Miguel P, Cigudosa JC (2008) Array CGH and gene-expression profiling reveals distinct genomic instability patterns associated with DNA repair and cell-cycle checkpoint pathways in Ewing’s sarcoma. Oncogene 27(14):2084–2090. doi:10.1038/sj.onc.1210845

    CAS  PubMed  Google Scholar 

  • Fu HL, Shao L, Wang Q, Jia T, Li M, Yang DP (2013) A systematic review of p53 as a biomarker of survival in patients with osteosarcoma. Tumour Biol 34(6):3817–3821. doi:10.1007/s13277-013-0966-x

    CAS  PubMed  Google Scholar 

  • Gaston LL, Di Bella C, Slavin J, Hicks RJ, Choong PF (2011) 18F-FDG PET response to neoadjuvant chemotherapy for Ewing sarcoma and osteosarcoma are different. Skeletal Radiol 40(8):1007–1015. doi:10.1007/s00256-011-1096-4

    PubMed  Google Scholar 

  • Gebhardt MC, Lew RA, Bell RS, Baldini N, Litwak G, Mankin HJ (1990) DNA ploidy as a prognostic indicator in human osteosarcoma. Chir Organi Mov 75(1 Suppl):18–21

    CAS  PubMed  Google Scholar 

  • Goorin AM, Schwartzentruber DJ, Devidas M, Gebhardt MC, Ayala AG, Harris MB, Helman LJ, Grier HE, Link MP (2003) Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J Clin Oncol 21(8):1574–1580. doi:10.1200/JCO.2003.08.165

    CAS  PubMed  Google Scholar 

  • Gorlick R, Huvos AG, Heller G, Aledo A, Beardsley GP, Healey JH, Meyers PA (1999) Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J Clin Oncol 17(9):2781–2788

    CAS  PubMed  Google Scholar 

  • Grant CE, Valdimarsson G, Hipfner DR, Almquist KC, Cole SP, Deeley RG (1994) Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res 54(2):357–361

    CAS  PubMed  Google Scholar 

  • Graves DT, Owen AJ, Barth RK, Tempst P, Winoto A, Fors L, Hood LE, Antoniades HN (1984) Detection of c-sis transcripts and synthesis of PDGF-like proteins by human osteosarcoma cells. Science 226(4677):972–974

    CAS  PubMed  Google Scholar 

  • Halperin EC (2011) Pediatric radiation oncology, 5th edn. Lippincott, Williams & Wilkins, Philadelphia

    Google Scholar 

  • Han G, Wang Y, Bi W (2012) C-Myc overexpression promotes osteosarcoma cell invasion via activation of MEK-ERK pathway. Oncol Res 20(4):149–156

    PubMed  Google Scholar 

  • Hattinger CM, Rumpler S, Strehl S, Ambros IM, Zoubek A, Potschger U, Gadner H, Ambros PF (1999) Prognostic impact of deletions at 1p36 and numerical aberrations in Ewing tumors. Genes Chromosomes Cancer 24(3):243–254

    CAS  PubMed  Google Scholar 

  • Hauben EI, Weeden S, Pringle J, Van Marck EA, Hogendoorn PC (2002) Does the histological subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma Intergroup. Eur J Cancer 38(9):1218–1225

    CAS  PubMed  Google Scholar 

  • Hayes DF, Bast RC, Desch CE, Fritsche H Jr, Kemeny NE, Jessup JM, Locker GY, Macdonald JS, Mennel RG, Norton L, Ravdin P, Taube S, Winn RJ (1996) Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 88(20):1456–1466

    CAS  PubMed  Google Scholar 

  • Hingorani P, Dickman P, Garcia-Filion P, White-Collins A, Kolb EA, Azorsa DO (2013) BIRC5 expression is a poor prognostic marker in Ewing sarcoma. Pediatr Blood Cancer 60(1):35–40. doi:10.1002/pbc.24290

    CAS  PubMed  Google Scholar 

  • Huang HY, Illei PB, Zhao Z, Mazumdar M, Huvos AG, Healey JH, Wexler LH, Gorlick R, Meyers P, Ladanyi M (2005) Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse. J Clin Oncol 23(3):548–558. doi:10.1200/JCO.2005.02.081

    CAS  PubMed  Google Scholar 

  • Hudson M, Jaffe MR, Jaffe N, Ayala A, Raymond AK, Carrasco H, Wallace S, Murray J, Robertson R (1990) Pediatric osteosarcoma: therapeutic strategies, results, and prognostic factors derived from a 10-year experience. J Clin Oncol 8(12):1988–1997

    CAS  PubMed  Google Scholar 

  • Huvos AG (1988) Surgical pathology of bone sarcomas. World J Surg 12(3):284–298

    CAS  PubMed  Google Scholar 

  • Jahromi MS, Putnam AR, Druzgal C, Wright J, Spraker-Perlman H, Kinsey M, Zhou H, Boucher KM, Randall RL, Jones KB, Lucas D, Rosenberg A, Thomas D, Lessnick SL, Schiffman JD (2012) Molecular inversion probe analysis detects novel copy number alterations in Ewing sarcoma. Cancer Genet 205(7-8):391–404. doi:10.1016/j.cancergen.2012.05.012

    CAS  PubMed Central  PubMed  Google Scholar 

  • Janeway KA, Barkauskas DA, Krailo MD, Meyers PA, Schwartz CL, Ebb DH, Seibel NL, Grier HE, Gorlick R, Marina N (2012) Outcome for adolescent and young adult patients with osteosarcoma: a report from the Children’s Oncology Group. Cancer 118(18):4597–4605. doi:10.1002/cncr.27414

    PubMed Central  PubMed  Google Scholar 

  • Jentzsch T, Robl B, Husmann M, Bode-Lesniewska B, Fuchs B (2014) Worse prognosis of osteosarcoma patients expressing IGF-1 on a tissue microarray. Anticancer Res 34(8):3881–3889, doi: 34/8/3881 [pii]

    PubMed  Google Scholar 

  • Kashima TG, Dongre A, Oppermann U, Athanasou NA (2013) Dentine matrix protein 1 (DMP-1) is a marker of bone-forming tumours. Virchows Arch 462(5):583–591. doi:10.1007/s00428-013-1399-z

    CAS  PubMed  Google Scholar 

  • Kim DH, Kim SY, Lee HJ, Song BS, Cho JB, Lim JS, Lee JA (2011) Assessment of chemotherapy response using FDG-PET in pediatric bone tumors: a single institution experience. Cancer Res Treat 43(3):170–175. doi:10.4143/crt.2011.43.3.170

    PubMed Central  PubMed  Google Scholar 

  • Kobayashi E, Masuda M, Nakayama R, Ichikawa H, Satow R, Shitashige M, Honda K, Yamaguchi U, Shoji A, Tochigi N, Morioka H, Toyama Y, Hirohashi S, Kawai A, Yamada T (2010) Reduced argininosuccinate synthetase is a predictive biomarker for the development of pulmonary metastasis in patients with osteosarcoma. Mol Cancer Ther 9(3):535–544. doi:10.1158/1535-7163.MCT-09-0774

    CAS  PubMed  Google Scholar 

  • Kochevar DT, Kochevar J, Garrett L (1990) Low level amplification of c-sis and c-myc in a spontaneous osteosarcoma model. Cancer Lett 53(2-3):213–222

    CAS  PubMed  Google Scholar 

  • Kong C, Hansen MF (2009) Biomarkers in osteosarcoma. Expert Opin Med Diagn 3(1):13–23. doi:10.1517/17530050802608496

    CAS  PubMed Central  PubMed  Google Scholar 

  • Kovar H, Jug G, Aryee DN, Zoubek A, Ambros P, Gruber B, Windhager R, Gadner H (1997) Among genes involved in the RB dependent cell cycle regulatory cascade, the p16 tumor suppressor gene is frequently lost in the Ewing family of tumors. Oncogene 15(18):2225–2232. doi:10.1038/sj.onc.1201397

    CAS  PubMed  Google Scholar 

  • Kruzelock RP, Murphy EC, Strong LC, Naylor SL, Hansen MF (1997) Localization of a novel tumor suppressor locus on human chromosome 3q important in osteosarcoma tumorigenesis. Cancer Res 57(1):106–109

    CAS  PubMed  Google Scholar 

  • Kullendorff CM, Mertens F, Donner M, Wiebe T, Akerman M, Mandahl N (1999) Cytogenetic aberrations in Ewing sarcoma: are secondary changes associated with clinical outcome? Med Pediatr Oncol 32(2):79–83

    CAS  PubMed  Google Scholar 

  • Ladanyi M, Cha C, Lewis R, Jhanwar SC, Huvos AG, Healey JH (1993a) MDM2 gene amplification in metastatic osteosarcoma. Cancer Res 53(1):16–18

    CAS  PubMed  Google Scholar 

  • Ladanyi M, Park CK, Lewis R, Jhanwar SC, Healey JH, Huvos AG (1993b) Sporadic amplification of the MYC gene in human osteosarcomas. Diagn Mol Pathol 2(3):163–167

    CAS  PubMed  Google Scholar 

  • Le Deley MC, Delattre O, Schaefer KL, Burchill SA, Koehler G, Hogendoorn PC, Lion T, Poremba C, Marandet J, Ballet S, Pierron G, Brownhill SC, Nesslböck M, Ranft A, Dirksen U, Oberlin O, Lewis IJ, Craft AW, Jürgens H, Kovar H (2010) Impact of EWS-ETS fusion type on disease progression in Ewing’s sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial. J Clin Oncol 28(12):1982–1988. doi:10.1200/JCO.2009.23.3585

    PubMed  Google Scholar 

  • Lee J, Hoang BH, Ziogas A, Zell JA (2010) Analysis of prognostic factors in Ewing sarcoma using a population-based cancer registry. Cancer 116(8):1964–1973. doi:10.1002/cncr.24937

    PubMed  Google Scholar 

  • Limmahakhun S, Pothacharoen P, Theera-Umpon N, Arpornchayanon O, Leerapun T, Luevitoonvechkij S, Pruksakorn D (2011) Relationships between serum biomarker levels and clinical presentation of human osteosarcomas. Asian Pac J Cancer Prev 12(7):1717–1722

    PubMed  Google Scholar 

  • Lin PP, Jaffe N, Herzog CE, Costelloe CM, Deavers MT, Kelly JS, Patel SR, Madewell JE, Lewis VO, Cannon CP, Benjamin RS, Yasko AW (2007) Chemotherapy response is an important predictor of local recurrence in Ewing sarcoma. Cancer 109(3):603–611. doi:10.1002/cncr.22412

    PubMed  Google Scholar 

  • Loe DW, Deeley RG, Cole SP (1996) Biology of the multidrug resistance-associated protein, MRP. Eur J Cancer 32A(6):945–957

    CAS  PubMed  Google Scholar 

  • Lopez Guerra JL, Marquez-Vega C, Ramirez-Villar GL, Cabrera P, Ordonez R, Praena-Fernandez JM, Ortiz MJ (2012) Prognostic factors for overall survival in paediatric patients with Ewing sarcoma of bone treated according to multidisciplinary protocol. Clin Transl Oncol 14(4):294–301. doi:10.1007/s12094-012-0798-y

    CAS  PubMed  Google Scholar 

  • Lopez-Guerrero JA, Machado I, Scotlandi K, Noguera R, Pellin A, Navarro S, Serra M, Calabuig-Fariñas S, Picci P, Llombart-Bosch A (2011) Clinicopathological significance of cell cycle regulation markers in a large series of genetically confirmed Ewing’s sarcoma family of tumors. Int J Cancer 128(5):1139–1150. doi:10.1002/ijc.25424

    CAS  PubMed  Google Scholar 

  • Lowichik A, Zhou H, Pysher TJ, Smith L, Lemons R, Coffin CM (2000) Therapy associated changes in childhood tumors. Adv Anat Pathol 7(6):341–359

    CAS  PubMed  Google Scholar 

  • MacEwen EG, Pastor J, Kutzke J, Tsan R, Kurzman ID, Thamm DH, Wilson M, Radinsky R (2004) IGF-1 receptor contributes to the malignant phenotype in human and canine osteosarcoma. J Cell Biochem 92(1):77–91. doi:10.1002/jcb.20046

    CAS  PubMed  Google Scholar 

  • Machado I, Lopez-Guerrero JA, Navarro S, Alberghini M, Scotlandi K, Picci P, Llombart-Bosch A (2012) Epithelial cell adhesion molecules and epithelial mesenchymal transition (EMT) markers in Ewing’s sarcoma family of tumors (ESFTs). Do they offer any prognostic significance? Virchows Arch 461(3):333–337. doi:10.1007/s00428-012-1288-x

    CAS  PubMed  Google Scholar 

  • Mackintosh C, Ordonez JL, Garcia-Dominguez DJ, Sevillano V, Llombart-Bosch A, Szuhai K, Scotlandi K, Alberghini M, Sciot R, Sinnaeve F, Hogendoorn PC, Picci P, Knuutila S, Dirksen U, Debiec-Rychter M, Schaefer KL, de Alava E (2012) 1q gain and CDT2 overexpression underlie an aggressive and highly proliferative form of Ewing sarcoma. Oncogene 31(10):1287–1298. doi:10.1038/onc.2011.317

    CAS  PubMed  Google Scholar 

  • Martin RC 2nd, Brennan MF (2003) Adult soft tissue Ewing sarcoma or primitive neuroectodermal tumors: predictors of survival? Arch Surg 138(3):281–285

    PubMed  Google Scholar 

  • Martin JW, Chilton-MacNeill S, Koti M, van Wijnen AJ, Squire JA, Zielenska M (2014) Digital expression profiling identifies RUNX2, CDC5L, MDM2, RECQL4, and CDK4 as potential predictive biomarkers for neo-adjuvant chemotherapy response in paediatric osteosarcoma. PLoS One 9(5), e95843. doi:10.1371/journal.pone.0095843

    PubMed Central  PubMed  Google Scholar 

  • McIntyre JF, Smith-Sorensen B, Friend SH, Kassell J, Borresen AL, Yan YX, Russo C, Sato J, Barbier N, Miser J et al (1994) Germline mutations of the p53 tumor suppressor gene in children with osteosarcoma. J Clin Oncol 12(5):925–930

    CAS  PubMed  Google Scholar 

  • McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2005) REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat Clin Pract Urol 2(8):416–422

    CAS  PubMed  Google Scholar 

  • Miller CW, Aslo A, Campbell MJ, Kawamata N, Lampkin BC, Koeffler HP (1996a) Alterations of the p15, p16, and p18 genes in osteosarcoma. Cancer Genet Cytogenet 86(2):136–142. doi: 0165-4608(95)00216-2 [pii]

    CAS  PubMed  Google Scholar 

  • Miller CW, Aslo A, Won A, Tan M, Lampkin B, Koeffler HP (1996b) Alterations of the p53, Rb and MDM2 genes in osteosarcoma. J Cancer Res Clin Oncol 122(9):559–565

    CAS  PubMed  Google Scholar 

  • Miser JS, Pritchard DJ, Rock MG, Shives TC, Gilchrist GS, Smithson WA, Arndt CA, Edmonson JH, Schaid DJ (1993) Osteosarcoma in adolescents and young adults: new developments and controversies. The Mayo Clinic studies. Cancer Treat Res 62:333–338

    CAS  PubMed  Google Scholar 

  • Moore C, Eslin D, Levy A, Roberson J, Giusti V, Sutphin R (2010) Prognostic significance of early lymphocyte recovery in pediatric osteosarcoma. Pediatr Blood Cancer 55(6):1096–1102. doi:10.1002/pbc.22673

    PubMed  Google Scholar 

  • Morris CD, Gorlick R, Huvos G, Heller G, Meyers PA, Healey JH (2001) Human epidermal growth factor receptor 2 as a prognostic indicator in osteogenic sarcoma. Clin Orthop Relat Res (382):59–65

    Google Scholar 

  • Nakashima H, Nishida Y, Sugiura H, Katagiri H, Yonekawa M, Yamada Y, Iwata H, Nagasaka T, Ishiguro N (2003) Telomerase, p53 and PCNA activity in osteosarcoma. Eur J Surg Oncol 29(7):564–567. doi: S0748798303001173 [pii]

    CAS  PubMed  Google Scholar 

  • Nardeux PC, Daya-Grosjean L, Landin RM, Andeol Y, Suarez HG (1987) A c-ras-Ki oncogene is activated, amplified and overexpressed in a human osteosarcoma cell line. Biochem Biophys Res Commun 146(2):395–402. doi: 0006-291X(87)90542-0 [pii]

    CAS  PubMed  Google Scholar 

  • Oberlin O, Deley MC, Bui BN, Gentet JC, Philip T, Terrier P, Carrie C, Mechinaud F, Schmitt C, Babin-Boillettot A, Michon J (2001) Prognostic factors in localized Ewing’s tumours and peripheral neuroectodermal tumours: the third study of the French Society of Paediatric Oncology (EW88 study). Br J Cancer 85(11):1646–1654. doi:10.1054/bjoc.2001.2150

    CAS  PubMed Central  PubMed  Google Scholar 

  • Onda M, Matsuda S, Higaki S, Iijima T, Fukushima J, Yokokura A, Kojima T, Horiuchi H, Kurokawa T, Yamamoto T (1996) ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma. Cancer 77(1):71–78. doi:10.1002/(SICI)1097-0142(19960101)77:1<71::AID-CNCR13>3.0.CO;2-5 [pii] 10.1002/(SICI)1097-0142(19960101)77:1<71::AID-CNCR13>3.0.CO;2-5

  • Ozaki T, Ikeda S, Kawai A, Inoue H, Oda T (1993) Alterations of retinoblastoma susceptible gene accompanied by c-myc amplification in human bone and soft tissue tumors. Cell Mol Biol (Noisy-le-Grand) 39(2):235–242

    CAS  Google Scholar 

  • Ozaki T, Paulussen M, Poremba C, Brinkschmidt C, Rerin J, Ahrens S, Hoffmann C, Hillmann A, Wai D, Schaefer KL, Boecker W, Juergens H, Winkelmann W, Dockhorn-Dworniczak B (2001) Genetic imbalances revealed by comparative genomic hybridization in Ewing tumors. Genes Chromosomes Cancer 32(2):164–171

    CAS  PubMed  Google Scholar 

  • Patino-Garcia A, Pineiro ES, Diez MZ, Iturriagagoitia LG, Klussmann FA, Ariznabarreta LS (2003) Genetic and epigenetic alterations of the cell cycle regulators and tumor suppressor genes in pediatric osteosarcomas. J Pediatr Hematol Oncol 25(5):362–367

    PubMed  Google Scholar 

  • Paulussen M, Ahrens S, Dunst J, Winkelmann W, Exner GU, Kotz R, Amann G, Dockhorn-Dworniczak B, Harms D, Müller-Weihrich S, Welte K, Kornhuber B, Janka-Schaub G, Göbel U, Treuner J, Voûte PA, Zoubek A, Gadner H, Jurgens H (2001a) Localized Ewing tumor of bone: final results of the cooperative Ewing’s Sarcoma Study CESS 86. J Clin Oncol 19(6):1818–1829

    CAS  PubMed  Google Scholar 

  • Paulussen M, Frohlich B, Jurgens H (2001b) Ewing tumour: incidence, prognosis and treatment options. Paediatr Drugs 3(12):899–913

    CAS  PubMed  Google Scholar 

  • Picci P, Rougraff BT, Bacci G, Neff JR, Sangiorgi L, Cazzola A, Baldini N, Ferrari S, Mercuri M, Ruggieri P et al (1993) Prognostic significance of histopathologic response to chemotherapy in nonmetastatic Ewing’s sarcoma of the extremities. J Clin Oncol 11(9):1763–1769

    CAS  PubMed  Google Scholar 

  • Picci P, Sangiorgi L, Rougraff BT, Neff JR, Casadei R, Campanacci M (1994) Relationship of chemotherapy-induced necrosis and surgical margins to local recurrence in osteosarcoma. J Clin Oncol 12(12):2699–2705

    CAS  PubMed  Google Scholar 

  • Picci P, Bohling T, Bacci G, Ferrari S, Sangiorgi L, Mercuri M, Ruggieri P, Manfrini M, Ferraro A, Casadei R, Benassi MS, Mancini AF, Rosito P, Cazzola A, Barbieri E, Tienghi A, Brach del Prever A, Comandone A, Bacchini P, Bertoni F (1997) Chemotherapy-induced tumor necrosis as a prognostic factor in localized Ewing’s sarcoma of the extremities. J Clin Oncol 15(4):1553–1559

    CAS  PubMed  Google Scholar 

  • Pinto A, Dickman P, Parham D (2011) Pathobiologic markers of the ewing sarcoma family of tumors: state of the art and prediction of behaviour. Sarcoma 2011:856190. doi:10.1155/2011/856190

    PubMed Central  PubMed  Google Scholar 

  • Provisor AJ, Ettinger LJ, Nachman JB, Krailo MD, Makley JT, Yunis EJ, Huvos AG, Betcher DL, Baum ES, Kisker CT, Miser JS (1997) Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children’s Cancer Group. J Clin Oncol 15(1):76–84

    CAS  PubMed  Google Scholar 

  • Qureshi SS, Kembhavi S, Vora T, Ramadwar M, Laskar S, Talole S, Kurkure P (2013) Prognostic factors in primary nonmetastatic Ewing sarcoma of the rib in children and young adults. J Pediatr Surg 48(4):764–770. doi:10.1016/j.jpedsurg.2012.07.049

    PubMed  Google Scholar 

  • Raymond AK, Chawla SP, Carrasco CH, Ayala AG, Fanning CV, Grice B, Armen T, Plager C, Papadopoulos NE, Edeiken J et al (1987) Osteosarcoma chemotherapy effect: a prognostic factor. Semin Diagn Pathol 4(3):212–236

    CAS  PubMed  Google Scholar 

  • Roberts P, Burchill SA, Brownhill S, Cullinane CJ, Johnston C, Griffiths MJ, McMullan DJ, Bown NP, Morris SP, Lewis IJ (2008) Ploidy and karyotype complexity are powerful prognostic indicators in the Ewing’s sarcoma family of tumors: a study by the United Kingdom Cancer Cytogenetics and the Children’s Cancer and Leukaemia Group. Genes Chromosomes Cancer 47(3):207–220. doi:10.1002/gcc.20523

    CAS  PubMed  Google Scholar 

  • Rodriguez-Galindo C, Navid F, Liu T, Billups CA, Rao BN, Krasin MJ (2008) Prognostic factors for local and distant control in Ewing sarcoma family of tumors. Ann Oncol 19(4):814–820. doi:10.1093/annonc/mdm521

    CAS  PubMed  Google Scholar 

  • Rosen G, Marcove RC, Caparros B, Nirenberg A, Kosloff C, Huvos AG (1979) Primary osteogenic sarcoma: the rationale for preoperative chemotherapy and delayed surgery. Cancer 43(6):2163–2177

    CAS  PubMed  Google Scholar 

  • Salzer-Kuntschik M, Delling G, Beron G, Sigmund R (1983) Morphological grades of regression in osteosarcoma after polychemotherapy – study COSS 80. J Cancer Res Clin Oncol 106(Suppl):21–24

    PubMed  Google Scholar 

  • Sanders RP, Drissi R, Billups CA, Daw NC, Valentine MB, Dome JS (2004) Telomerase expression predicts unfavorable outcome in osteosarcoma. J Clin Oncol 22(18):3790–3797. doi:10.1200/JCO.2004.03.043 22/18/3790 [pii]

    CAS  PubMed  Google Scholar 

  • Sankar S, Lessnick SL (2011) Promiscuous partnerships in Ewing’s sarcoma. Cancer Genet 204(7):351–365. doi:10.1016/j.cancergen.2011.07.008

    CAS  PubMed Central  PubMed  Google Scholar 

  • Sauer R, Jurgens H, Burgers JM, Dunst J, Hawlicek R, Michaelis J (1987) Prognostic factors in the treatment of Ewing’s sarcoma. The Ewing’s Sarcoma Study Group of the German Society of Paediatric Oncology CESS 81. Radiother Oncol 10(2):101–110

    CAS  PubMed  Google Scholar 

  • Savola S, Klami A, Tripathi A, Niini T, Serra M, Picci P, Kaski S, Zambelli D, Scotlandi K, Knuutila S (2009) Combined use of expression and CGH arrays pinpoints novel candidate genes in Ewing sarcoma family of tumors. BMC Cancer 9:17. doi:10.1186/1471-2407-9-17

    PubMed Central  PubMed  Google Scholar 

  • Scholz RB, Kabisch H, Weber B, Roser K, Delling G, Winkler K (1992) Studies of the RB1 gene and the p53 gene in human osteosarcomas. Pediatr Hematol Oncol 9(2):125–137. doi:10.3109/08880019209018328

    CAS  PubMed  Google Scholar 

  • Scotlandi K, Serra M, Manara MC, Maurici D, Benini S, Nini G, Campanacci M, Baldini N (1995) Clinical relevance of Ki-67 expression in bone tumors. Cancer 75(3):806–814

    CAS  PubMed  Google Scholar 

  • Shukla N, Schiffman J, Reed D, Davis IJ, Womer RB, Lessnick SL, Lawlor ER (2013) Biomarkers in Ewing sarcoma: the promise and challenge of personalized medicine. A Report from the Children’s Oncology Group. Front Oncol 3:141. doi:10.3389/fonc.2013.00141

    PubMed Central  PubMed  Google Scholar 

  • Simon RM, Paik S, Hayes DF (2009) Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 101(21):1446–1452. doi:10.1093/jnci/djp335

    PubMed Central  PubMed  Google Scholar 

  • Tarkkanen M, Kiuru-Kuhlefelt S, Blomqvist C, Armengol G, Bohling T, Ekfors T, Virolainen M, Lindholm P, Monge O, Picci P, Knuutila S, Elomaa I (1999) Clinical correlations of genetic changes by comparative genomic hybridization in Ewing sarcoma and related tumors. Cancer Genet Cytogenet 114(1):35–41

    CAS  PubMed  Google Scholar 

  • Ueda Y, Dockhorn-Dworniczak B, Blasius S, Mellin W, Wuisman P, Bocker W, Roessner A (1993) Analysis of mutant P53 protein in osteosarcomas and other malignant and benign lesions of bone. J Cancer Res Clin Oncol 119(3):172–178

    CAS  PubMed  Google Scholar 

  • van Doorninck JA, Ji L, Schaub B, Shimada H, Wing MR, Krailo MD, Lessnick SL, Marina N, Triche TJ, Sposto R, Womer RB, Lawlor ER (2010) Current treatment protocols have eliminated the prognostic advantage of type 1 fusions in Ewing sarcoma: a report from the Children’s Oncology Group. J Clin Oncol 28(12):1989–1994. doi:10.1200/JCO.2009.24.5845

    PubMed Central  PubMed  Google Scholar 

  • van Maldegem AM, Hogendoorn PC, Hassan AB (2012) The clinical use of biomarkers as prognostic factors in Ewing sarcoma. Clin Sarcoma Res 2(1):7. doi:10.1186/2045-3329-2-7

    PubMed Central  PubMed  Google Scholar 

  • Wagner LM, Smolarek TA, Sumegi J, Marmer D (2012) Assessment of minimal residual disease in ewing sarcoma. Sarcoma 2012:780129. doi:10.1155/2012/780129

    PubMed Central  PubMed  Google Scholar 

  • Wen J, Wang L, Zhang M, Xie D, Sun L (2002) Repression of telomerase activity during in vitro differentiation of osteosarcoma cells. Cancer Invest 20(1):38–45

    CAS  PubMed  Google Scholar 

  • Winkler K, Bielack SS, Delling G, Jurgens H, Kotz R, Salzer-Kuntschik M (1993) Treatment of osteosarcoma: experience of the Cooperative Osteosarcoma Study Group (COSS). Cancer Treat Res 62:269–277

    CAS  PubMed  Google Scholar 

  • Wold LE (1998) Practical approach to processing osteosarcomas in the surgical pathology laboratory. Pediatr Dev Pathol 1(5):449–454

    CAS  PubMed  Google Scholar 

  • Wu JX, Carpenter PM, Gresens C, Keh R, Niman H, Morris JW, Mercola D (1990) The proto-oncogene c-fos is over-expressed in the majority of human osteosarcomas. Oncogene 5(7):989–1000

    CAS  PubMed  Google Scholar 

  • Wu X, Cai ZD, Lou LM, Zhu YB (2012) Expressions of p53, c-MYC, BCL-2 and apoptotic index in human osteosarcoma and their correlations with prognosis of patients. Cancer Epidemiol 36(2):212–216. doi:10.1016/j.canep.2011.08.002

    CAS  PubMed  Google Scholar 

  • Wunder JS, Paulian G, Huvos AG, Heller G, Meyers PA, Healey JH (1998) The histological response to chemotherapy as a predictor of the oncological outcome of operative treatment of Ewing sarcoma. J Bone Joint Surg Am 80(7):1020–1033

    CAS  PubMed  Google Scholar 

  • Xie L, Guo W, Li Y, Ji T, Sun X (2012) Pathologic fracture does not influence local recurrence and survival in high-grade extremity osteosarcoma with adequate surgical margins. J Surg Oncol 106(7):820–825. doi:10.1002/jso.23150

    PubMed  Google Scholar 

  • Yang Y, Li H, Zhang F, Shi H, Zhen T, Dai S, Kang L, Liang Y, Wang J, Han A (2013) Clinical and biological significance of hepatoma-derived growth factor in Ewing’s sarcoma. J Pathol 231(3):323–334. doi:10.1002/path.4241

    CAS  PubMed  Google Scholar 

  • Yang Y, Zhen T, Zhang F, Dai S, Kang L, Liang Y, Xue L, Han A (2014) p53 and hepatoma-derived growth factor expression and their clinicopathological association with Ewing family tumour. J Clin Pathol 67(3):235–242. doi:10.1136/jclinpath-2013-201705

    PubMed  Google Scholar 

  • Zhang Y, Zhang L, Zhang G, Li S, Duan J, Cheng J, Ding G, Zhou C, Zhang J, Luo P, Cai D, Kuang L, Zhou Y, Tong L, Yu X, Zhang L, Xu L, Yu L, Shi X, Ke A (2014) Osteosarcoma metastasis: prospective role of ezrin. Tumour Biol 35(6):5055–5059. doi:10.1007/s13277-014-1799-y

    CAS  PubMed  Google Scholar 

  • Zielenska M, Zhang ZM, Ng K, Marrano P, Bayani J, Ramirez OC, Sorensen P, Thorner P, Greenberg M, Squire JA (2001) Acquisition of secondary structural chromosomal changes in pediatric ewing sarcoma is a probable prognostic factor for tumor response and clinical outcome. Cancer 91(11):2156–2164

    CAS  PubMed  Google Scholar 

  • Zuo D, Zheng L, Sun W, Hua Y, Cai Z (2013) Pathologic fracture does not influence prognosis in stage IIB osteosarcoma: a case-control study. World J Surg Oncol 11:148. doi:10.1186/1477-7819-11-148

    PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology/Oncology/BMT, Nationwide Children’s Hospital, 700 Children’s Drive, Columbus, OH, 43205, USA

    Kellie B. Haworth & Bhuvana A. Setty

Authors
  1. Kellie B. Haworth
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bhuvana A. Setty
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kellie B. Haworth .

Editor information

Editors and Affiliations

  1. Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Nationwide Children’s Hospital, Columbus, Ohio, USA

    Timothy P. Cripe

  2. Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Nationwide Children’s Hospital, Columbus, Ohio, USA

    Nicholas D. Yeager

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Haworth, K.B., Setty, B.A. (2015). Histological Response and Biological Markers. In: Cripe, T., Yeager, N. (eds) Malignant Pediatric Bone Tumors - Treatment & Management. Pediatric Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-18099-1_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-18099-1_8

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-18098-4

  • Online ISBN: 978-3-319-18099-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation